Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00275418|
Recruitment Status : Unknown
Verified January 2006 by Bnai Zion Medical Center.
Recruitment status was: Recruiting
First Posted : January 12, 2006
Last Update Posted : January 12, 2006
Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.
Beta carotene is an anti-oxidant vitamin present in many fruits and vegetables. The algae Dunaliella is particularly rich in beta carotene.
In this prospective trial we want to investigate whether beta carotene from Dunaliella may prevent exacerbations of Crohn's disease.
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease||Drug: beta carotene from Dunaliella algae||Phase 3|
Patients with documented Crohn's disease who are at least 2 months in remission (CDAI<150) will be randomized to receive 60 mg beta carotene/day vs. placebo for 1 year.
The study medication will be taken in addition to regular treatment for Crohn's disease.
The protocol includes 5 visits (months 0, 3, 6, 9, 12). Each visit lasts 30-60 minutes and includes a brief interview, standard questionnaires, physical examination, and blood tests.
Exacerbation of Crohn's disease is defined as CDAI>150. The study hypothesis is that less patients treated with beta carotene will suffer an exacerbation than patients treated with placebo.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission|
|Study Start Date :||July 2002|
- CDAI score measured 3-monthly during treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00275418
|Contact: Matthias Carlebach, MD||+ firstname.lastname@example.org|
|Contact: Alexandra Lavy, MD||+ email@example.com|
|Bnai Zion Medical Center||Recruiting|
|Haifa, Israel, 31048|
|Contact: Matthias Carlebach, MD + 972-4-8359426 firstname.lastname@example.org|
|Contact: Alexandra Lavy, MD + 972-4-8359736 email@example.com|
|Sub-Investigator: Matthias Carlebach, MD|
|Principal Investigator:||Alexandra Lavy, MD||Technion, Haifa, Israel|